The development and use of the E75 (HER2 369-377) peptide vaccine.

about

ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Treating breast cancer with cell-based approaches: an overview.Effects of recombinant Agrocybe aegerita lectin as an immunoadjuvant on immune responses.

P2860

Q33772914-A9F7417B-B515-458B-AFC6-BDEE81EE78F2 Q39448180-19254007-E42D-403C-8B6B-D174426AD3EC Q47598017-2FF0EA81-EFFE-496B-A7BA-10D466A32EF1

P2860

The development and use of the E75 (HER2 369-377) peptide vaccine.

Item

http://www.wikidata.org/entity/Q38885965

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

The development and use of the E75 (HER2 369-377) peptide vaccine.

@en

type

Item

label

The development and use of the E75 (HER2 369-377) peptide vaccine.

@en

prefLabel

The development and use of the E75 (HER2 369-377) peptide vaccine.

@en

P1476

The development and use of the E75 (HER2 369-377) peptide vaccine.

@en

P2093

Elizabeth A Mittendorf

http://www.w3.org/2001/XMLSchema#string

George E Peoples

http://www.w3.org/2001/XMLSchema#string

Guy T Clifton

http://www.w3.org/2001/XMLSchema#string

P2860

A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer.

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines.

Cytotoxic T-cell precursor frequencies to HER-2 (369-377) in patients with HER-2/neu-positive epithelial tumours

Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion.

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2.

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.

Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer.

P304

1321-1329

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2015-0054

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27044454

http://www.w3.org/2001/XMLSchema#string

P932

6040084

http://www.w3.org/2001/XMLSchema#string

The development and use of the E75 (HER2 369-377) peptide vaccine.

about

P2860

P2860

The development and use of the E75 (HER2 369-377) peptide vaccine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932